Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 LIUZi-li ¹ ,  HUANGLi-nian ² , WANGBin ¹ , LIUJi-zhu ¹ , LIUWei-wei ¹

1. Department of Respiratory Diseases, Huaibei Miners General Hospital, Huaibei 235000, China;
2. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China;

Corresponding?author：

HUANGLi-nian, Email: bbmchln@126.com

Keywords：

Endostar; Cisplatin; Non-small cell lung cancer; Malignant pleural effusion; Meta-analysis; Randomized controlled trial

DOI：

10.7507/1672-2531.20160086

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of intrapleural injection of endostar combined with cisplatin in treatment of non-small cell lung cancer (NSCLC) with malignant pleural effusion. Methods Databases including PubMed, The Cochrane Library (Issue 2, 2016), EMbase, Web of Science, CNKI, VIP and WanFang Data were searched to collect randomized controlled trials (RCTs) about endostar combined with cisplatin for NSCLC with malignant pleural effusion from inception to February 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by using RevMan 5.3 software. Results A total of 10 RCTs involving 610 patients were finally included. The results of meta-analysis showed that: The overall response rate and the improvement rate of quality of life in the endostar combined with cisplatin group were higher than that of the cisplatin alone group (RR=1.71, 95%CI 1.49 to 1.95, P<0.00001; RR=1.68, 95%CI 1.44 to 1.96, P<0.00001, respectively). However, There were no significant differences between two groups in incidence of gastrointestinal reaction, incidence of leucopenia and incidence of thrombocytopenia (all P values>0.05). Conclusion Compared with cisplatin, intrapleural injection of endostar combined with cisplatin can improve the overall response rate and improve the quality of life of NSCLC patients with malignant pleural effusion. Due to the limited quality and quantity of included studies, more high quality studies are needed to verify the above conclusion.

Citation： LIUZi-li, HUANGLi-nian, WANGBin, LIUJi-zhu, LIUWei-wei. Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(5): 557-563. doi: 10.7507/1672-2531.20160086 Copy

1.	Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin, 2014, 64(1): 9-29.
2.	Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori, 2012, 98(3): 314-319.
3.	段春霞, 梁曉光, 張志強. 恩度聯合順鉑治療非小細胞肺癌惡性胸腔積液的療效分析. 包頭醫學院學報, 2015, 31(2): 45-46.
4.	鄭勤紅, 胡偉, 廖小方, 等. 順鉑序貫恩度與單純順鉑胸腔內灌注治療惡性胸腔積液的臨床對照研究. 腫瘤學雜志, 2013, 19(5): 386-389.
5.	Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
6.	劉欣, 王麗萍. 重組人血管內皮抑制素聯合順鉑腔內化療治療非小細胞肺癌合并惡性胸腔積液臨床觀察. 腫瘤基礎與臨床, 2012, 25(3): 233-235.
7.	劉維, 哈敏文, 殷南昌, 等. 恩度聯合順鉑胸腔內注射治療非小細胞肺癌惡性胸腔積液臨床研究. 山東醫藥, 2010, 50(8): 79-80.
8.	岳國軍, 柏玉舉, 馬虎, 等. 順鉑聯合恩度治療非小細胞肺癌血性胸腔積液的療效和安全性分析. 現代診斷與治療, 2014, 25(11): 2478-2480.
9.	李文燕. 恩度胸腔內灌注治療惡性胸腔積液療效觀察. 醫藥論壇雜志, 2011, 32(7): 170-171.
10.	楊勇, 林潤英, 曹官銘. 恩度聯合順鉑治療非小細胞肺癌惡性胸腔積液近遠期療效. 中國藥業, 2013, 22(19): 21-22.
11.	沈清, 顧愛琴, 武建毅, 等. 重組人血管內皮抑制素聯合順鉑治療非小細胞肺癌惡性胸腔積液療效觀察. 實用臨床醫藥雜志, 2012, 16(5): 29-31.
12.	涂建仁, 黃淑娟, 王美鑑. 重組人血管內皮抑制素聯合順鉑胸腔灌注治療晚期非小細胞肺癌惡性胸腔積液的臨床療效. 實用癌癥雜志, 2014, 29(12): 1592-1594.
13.	陳潔, 茍淑萍, 欒文革. 重組人血管內皮抑制素聯合順鉑治療非小細胞肺癌惡性胸腔積液的療效及對VEGF、HIF-1α、腫瘤標志物的影響. 臨床和實驗醫學雜志, 2014, 13(21): 1778-1780.
14.	黃柬. 恩度聯合順鉑胸腔內灌注治療惡性胸腔積液療效觀察. 實用臨床醫藥雜志, 2010, 14(7): 63-64.
15.	黃莉. 恩度聯合順鉑治療非小細胞肺癌惡性胸腔積液的臨床觀察. 吉林醫學, 2014, 35(19): 4308-4309.
16.	何文杰, 江波, 李佳. 中心靜脈導管閉式引流聯合白細胞介素2腔內灌注在晚期肺癌并惡性胸腔積液中的應用. 重慶醫學, 2013, 42(4): 445-447.
17.	徐繼平, 周蕾, 楊衛兵. 恩度聯合順鉑胸腔內灌注治療非小細胞肺癌惡性胸腔積液研究進展. 大連醫科大學學報, 2015, 37(1): 89-92.
18.	吳凱, 盧慧宇, 段德軍. 恩度聯合順鉑胸腔內注射治療非小細胞肺癌惡性胸腔積液臨床觀察. 臨床肺科雜志, 2012, 17(1): 107-108.
19.	Folkman J. Anti-angiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
20.	王金萬, 孫燕, 劉永煜, 等. 重組人血管內皮抑素聯合NP方案治療晚期NSCLC隨機、雙盲、對照、多中心Ⅲ期臨床研究. 中國肺癌雜志, 2005, 8(4): 283-290.
21.	Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.
22.	Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs, 2005, 16(5): 551-557.
23.	Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One, 2012, 7(12): e53449.
24.	Fan J, DU J, Wu J, et al. Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett, 2015, 9(2): 822-828.

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics. CA Cancer J Clin, 2014, 64(1): 9-29.
2. Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori, 2012, 98(3): 314-319.
3. 段春霞, 梁曉光, 張志強. 恩度聯合順鉑治療非小細胞肺癌惡性胸腔積液的療效分析. 包頭醫學院學報, 2015, 31(2): 45-46.
4. 鄭勤紅, 胡偉, 廖小方, 等. 順鉑序貫恩度與單純順鉑胸腔內灌注治療惡性胸腔積液的臨床對照研究. 腫瘤學雜志, 2013, 19(5): 386-389.
5. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane-handbook.org.
6. 劉欣, 王麗萍. 重組人血管內皮抑制素聯合順鉑腔內化療治療非小細胞肺癌合并惡性胸腔積液臨床觀察. 腫瘤基礎與臨床, 2012, 25(3): 233-235.
7. 劉維, 哈敏文, 殷南昌, 等. 恩度聯合順鉑胸腔內注射治療非小細胞肺癌惡性胸腔積液臨床研究. 山東醫藥, 2010, 50(8): 79-80.
8. 岳國軍, 柏玉舉, 馬虎, 等. 順鉑聯合恩度治療非小細胞肺癌血性胸腔積液的療效和安全性分析. 現代診斷與治療, 2014, 25(11): 2478-2480.
9. 李文燕. 恩度胸腔內灌注治療惡性胸腔積液療效觀察. 醫藥論壇雜志, 2011, 32(7): 170-171.
10. 楊勇, 林潤英, 曹官銘. 恩度聯合順鉑治療非小細胞肺癌惡性胸腔積液近遠期療效. 中國藥業, 2013, 22(19): 21-22.
11. 沈清, 顧愛琴, 武建毅, 等. 重組人血管內皮抑制素聯合順鉑治療非小細胞肺癌惡性胸腔積液療效觀察. 實用臨床醫藥雜志, 2012, 16(5): 29-31.
12. 涂建仁, 黃淑娟, 王美鑑. 重組人血管內皮抑制素聯合順鉑胸腔灌注治療晚期非小細胞肺癌惡性胸腔積液的臨床療效. 實用癌癥雜志, 2014, 29(12): 1592-1594.
13. 陳潔, 茍淑萍, 欒文革. 重組人血管內皮抑制素聯合順鉑治療非小細胞肺癌惡性胸腔積液的療效及對VEGF、HIF-1α、腫瘤標志物的影響. 臨床和實驗醫學雜志, 2014, 13(21): 1778-1780.
14. 黃柬. 恩度聯合順鉑胸腔內灌注治療惡性胸腔積液療效觀察. 實用臨床醫藥雜志, 2010, 14(7): 63-64.
15. 黃莉. 恩度聯合順鉑治療非小細胞肺癌惡性胸腔積液的臨床觀察. 吉林醫學, 2014, 35(19): 4308-4309.
16. 何文杰, 江波, 李佳. 中心靜脈導管閉式引流聯合白細胞介素2腔內灌注在晚期肺癌并惡性胸腔積液中的應用. 重慶醫學, 2013, 42(4): 445-447.
17. 徐繼平, 周蕾, 楊衛兵. 恩度聯合順鉑胸腔內灌注治療非小細胞肺癌惡性胸腔積液研究進展. 大連醫科大學學報, 2015, 37(1): 89-92.
18. 吳凱, 盧慧宇, 段德軍. 恩度聯合順鉑胸腔內注射治療非小細胞肺癌惡性胸腔積液臨床觀察. 臨床肺科雜志, 2012, 17(1): 107-108.
19. Folkman J. Anti-angiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 2006, 312(5): 594-607.
20. 王金萬, 孫燕, 劉永煜, 等. 重組人血管內皮抑素聯合NP方案治療晚期NSCLC隨機、雙盲、對照、多中心Ⅲ期臨床研究. 中國肺癌雜志, 2005, 8(4): 283-290.
21. Zhao WY, Chen DY, Chen JH, et al. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys, 2014, 70(1): 623-628.
22. Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs, 2005, 16(5): 551-557.
23. Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One, 2012, 7(12): e53449.
24. Fan J, DU J, Wu J, et al. Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett, 2015, 9(2): 822-828.

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Endostar Combined with Cisplatin in Treatment of Non-Small Cell Lung Cancer with Malignant Pleural Effusion: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content